ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY
Sydney, Australia & Auckland, New Zealand - 4 November 2022 - Living Cell Technologies (ASX:LCT; OTCQB:LVCLY) references the Company's announcement of 27 October 2022 and advises shareholders that the online attendance option for the 2022 Annual General Meeting (AGM) has now been cancelled.
The Company is focused on managing corporate overheads to maximise R&D expenditure and the costs associated with a hybrid service are prohibitive.
The AGM will be held from 2pm AEDT on Thursday, 10 November 2022 at the Royal Australian Automobile Club, Macquarie Room, 89 Macquarie St, Sydney, NSW, 2000.
Shareholders who cannot attend in person are encouraged to email any questions to the Company.
Authorised for release by the Board of Living Cell Technologies Limited.
For further information: www.lctglobal.com
| At the Company: Bradley Dilkes Director Mobile: +61 422 180 317 brad@lctglobal.com | For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au |
About Living Cell Technologies
Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.
LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.
For more information, visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.
References to previous ASX releases
Forward-looking statements
This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
| © Copyright 1996-2025 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |